Canada signs agreements to potentially share drug information with the US and Australia

Blouin, Dan
July 2004
CMAJ: Canadian Medical Association Journal;7/20/2004, Vol. 171 Issue 2, p121
Academic Journal
Deals with an agreement signed by Health Canada with the U.S. and Australia which will result to faster drug approval in both countries. Terms of the deal negotiated between Health Canada's Health Products and Food Branch and the Therapeutic Goods Administration in the Department of Health and Aeging in Australia; Benefits of the deals to Health Canada; Criticism being faced by the two deals.


Related Articles

  • TGA, Health Canada, agree to QS certifications.  // Medical Device Daily;10/27/2010, Vol. 14 Issue 209, p9 

    The article reports on a memorandum of understanding between Australia's Therapeutic Goods Administration and Health Canada concerning reciprocal recognition of quality management system certifications for medical device manufacturers.

  • Health authorities issue advisories over adulterated health products.  // Reactions Weekly;7/31/2010, Issue 1312, p6 

    The article reports on the issuance of three new advisories by health authorities in Australia and Canada on natural or herbal medicines that may contain potentially harmful ingredients. Consumers were advised by Australia's Therapeutic Goods Administration (TGA) to stop using the product 1 Body...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;3/7/2009, Issue 1242, p2 

    The article reports on Foreign Product Alert issued by Health Canada regarding Nyal Day & Night Cold & Flu Fighter and Nyal Cold & Flu Fighter, as the Australian Therapeutic Goods Administration has advised that the products have been associated with serious allergic reactions, including...

  • Important safety updates for dabigatran etexilate.  // Reactions Weekly;11/19/2011, Issue 1378, p3 

    The article focuses on safety alerts and recommendations issued in 2011 for using dabigatran etexelate. In Great Britain, Boehringer Ingelheim has issued a letter addressed to clinicians stressing the importance of evaluating renal function in patients receiving dabigatran etexilate. The...

  • Medical devices TGA update.  // Australasian Biotechnology;Mar2009, Vol. 19 Issue 1, p10 

    The article provides an update on the Australian Therapeutic Goods Administration (TGA) and the regulation of medical devices in Australia, as of March 2009. Submissions on the use of third party conformity assessment bodies for medical devices supplied in Australia has been called for by TGA....

  • Australian TGA warns of exenatide-induced pancreatitis.  // Reactions Weekly;6/5/2010, Issue 1304, p2 

    The article deals with the public advisory issued by the Australian Therapeutic Goods Administration (TGA) in June 2010 regarding exenatide-induced pancreatitis.

  • Australian TGA updates safety info for varenicline.  // Reactions Weekly;8/7/2010, Issue 1313, p6 

    The article reports on an update issued by the Australian Therapeutic Goods Administration (TGA) on the safety of varenicline (Champix), including its associated psychiatric side effects.

  • TGA advises of dosing change for citalopram.  // Reactions Weekly;11/12/2011, Issue 1377, p3 

    The article reports on the recommendation by the Australian Therapeutic Goods Administration (TGA) that citalopram no longer be administered at dosages of less than 40 milligrams (mg)/day.

  • Combination antihypertensive approved.  // Australian Journal of Pharmacy;Apr2011, Vol. 92 Issue 1091, p52 

    The article offers information on the approval of the fixed-dose combination therapy, Twynsta, by the Therapeutic Goods Administration (TGA) in Australia.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics